- Lexaria’s
fast-acting, high absorption technology will improve dipping experience
and consumer satisfaction
- Partnership
will enable Lexaria’s to provide its DehydraTECH(TM) drug delivery
platform to Cannadips Cannnabis products in California and nationwide
- Cannadips
to open one-of-a-kind cannabis oral pouch and dip research facility
Global innovators in drug delivery platforms Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) will
provide its patented DehydraTECH(TM) technology to Cannadips Cannabis for use
on the latter’s market in California and nationwide according to a new
definitive agreement. Currently, Cannadips Cannabis Tins are sold in
California. Each tin contains 15 pouches with 10 mg of tetrahydrocannabinol
each, no nicotine, no tobacco, and all-natural sweeteners. The company also has
a high-dose version with 15 pouches and 20 mg of cannabis-derived THC
each (http://ibn.fm/N0pdA).
Lexaria’s DehydraTECH(TM) drug delivery platform is
perfectly suited to improve the dipping experience through its effective, high
absorption technology. Cannadips uses multi spectrum oils as base ingredients.
The oils are rich in high-quality terpenes, which ensure the much-coveted
entourage effect. DehydraTECH(TM) minimizes the throat irritation usually
associated with some terpenes.
“Lexaria is building a stronger relationship with the
Cannadips brand and applying DehydraTECH to Cannadips cannabis represents our
latest advance,” Chris Bunka, CEO of Lexaria Bioscience Corp., stated in a news
release. “Our DehydraTECH technology empowers a scalable supply chain across
state lines for our cannabis brand licensees. We are excited that Cannadips is
interested in activating the Lexaria technology in additional key state
markets.”
The licensing agreement provided by Lexaria grants Cannadips
exclusive rights for this product format for the U.S. market for 10 years, with
the option to expand the license to Canada, Mexico and/or Europe.
According to Case Mandel, co-founder and chief executive
officer of Cannadips Cannabis, the agreement will allow Cannadips to partner
with operators in other states and bring its cannabis technology across state
lines. “Our cannabis oral pouch and dip research facility in Humboldt is going
to be the first of its kind in our brand new 4,000 square foot facility. We are
also highly interested in activating the Canadian Oral Pouch Cannabinoid
market,” Mandel added. Cannadips’ new 4,000 square foot oral cannabinoid
research and development facility in Arcata, California will house
manufacturing, corporate offices, distribution, and retail.
Lexaria Bioscience has launched a revolutionary technology
that accelerates intestinal absorption of bioactive substances administered
without the need for inhalational dosing, co-administration with sweeteners or
sugars, and other unhealthy practices. It is applicable to absorption of
cannabis and nicotine, among other bioactive substances (http://ibn.fm/GdBAc). The
DehydraTECH(TM) drug delivery platform is patented for all non-psychoactive
cannabinoids as well as for tetrahydrocannabinol and psychoactive cannabinoids.
The platform reduces the time of onset of THC by four times on average (http://ibn.fm/DHOzB).
Lexaria is the leading company in the world that holds
patents for oral delivery of all cannabinoids. The company holds 60 globally
pending patents. Recently, Lexaria obtained two patents for treating certain
conditions including, but not limited to, heart disease, neurological diseases
such as Alzheimer’s, Parkinson’s, schizophrenia and others. The technology has
potential applications to assist treatment of the common form of dementia as
well as other nervous system diseases.
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
